Board Of Directors
John Berriman is the Chairman of Heptares Therapeutics Ltd and past Chairman (now deputy Chairman) of Algeta ASA (OSE.ALGETA). He is also a non-executive director of Cytos AG (SW.CYTN) and ReNeuron Group PLC (L.RENE). Until its sale to Amgen in the spring of 2012 he was a director of MicroMet, Inc. (NASDAQ.MITI). Previously he was a director of Abingworth Management, an international healthcare venture capital firm, where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA, many of which obtained listings on public stock exchanges. Prior to that, he spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.
Charles H. Large, PhD
(Chief Executive Officer)
Charles Large received his first degree and PhD from the University of Bristol and has more than 20 years of experience of drug discovery and development in the pharmaceutical industry. Before founding Autifony, he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline, and has worked on programs focused on schizophrenia, Alzheimer's disease, epilepsy, bipolar disorder, and major depression. He is an expert on drugs that modulate voltage gated ion channels and their application to neurological and psychiatric disorders. He has built up a reputation in the field of sodium channel blocking drugs, and has collaborated widely with academic groups. He has authored over 50 papers, book chapters and patents relating to ion channel modulators.
Kate Bingham joined SVLS in 1991. Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed, RespiVert and current investments including Autifony, Bicycle, Convergence and TopiVert. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.
Maina Bhaman is Director of Healthcare Investments at Imperial Innovations. Maina has led a number of investments in Imperial Innovations' healthcare portfolio including recent investments into Psioxus Therapeutics and Cellmedica . Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico, Psioxus Therapeutics and Topivert Pharma. Maina was also served on the board of Acrobot and Molecular Vision Ltd. Maina joined Innovations in 2006 and prior to that worked in the research and development team at Celltech (previously Oxford Glyco Sciences). Maina's experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia and GeneMedicine, a gene therapy company based in Houston, Tx. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.
Elaine V. Jones, Ph.D. is an Executive Director, Venture Capital, with Pfizer Venture Investments. She is responsible for making and managing venture investments for Pfizer and currently manages the PVI investments in Aquinox Pharmaceuticals, Flexion Therapeutics, Merus, MIRNA Therapeutics, Neuronetics and TetraLogic Pharmaceuticals. Elaine brings 10 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.
Elaine was a General Partner with EuclidSR Partners, where she was responsible for the fund's investments in Acurian, Fluidigm, InnaPhase and Targacept. Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing and was a research scientist in SmithKline Beecham. Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.
Atul Pande, M.D., is President of Verity BioConsulting, an independent drug development consulting firm. Previously he was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. For more than two decades he has been active in the development of many important CNS drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes pre-IND development, proof of concept to registration development, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer’s and Parkinson’s disease. Most recently he was also instrumental in the NDA and MAA submission and approval of medicines for asthma, COPD, HIV and cancer.
Atul is a psychiatrist and Fellow of several scientific societies. He began his career as a faculty member at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.